Nektar Therapeutics (NKTR) Tops Q4 EPS by 4c, Revenues Beat

Nektar Therapeutics (NASDAQ: NKTR) reported Q4 EPS of ($0.64), $0.04 better than the analyst estimate of ($0.68). Revenue for the quarter came in at $33.86 million versus the consensus estimate of $26.93 million.

"Nektar's progress over the past year has established a strong foundation for growth, with a robust portfolio of clinical-stage immuno-oncology and immunology candidates addressing multiple therapeutic areas," said Howard W. Robin, President and CEO of Nektar. "Our amended joint development plan with Bristol-Myers Squibb for bempegaldesleukin in combination with Opdivo expands the active registrational program for the doublet to five indications, including new Phase 3 studies in the adjuvant melanoma setting and muscle invasive bladder cancer. It also provides a path forward in first-line lung cancer and enhances our ability to pursue new combinations in additional indications."

Mr. Robin continued, "We also advanced NKTR-255, a novel IL-15 agonist that stimulates NK cells and memory T cells, into the clinic in combination with ADCC therapies. With NKTR-358, we have an opportunity to address the underlying immune imbalance associated with multiple autoimmune and chronic inflammatory diseases. Our partner Eli Lilly is on track to initiate a Phase 2 study in lupus, advance ongoing Phase 1b clinical trials in psoriasis and atopic dermatitis, and start an additional Phase 2 study in a new autoimmune indication this year."

For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.

You May Also Be Interested In

• John Rogers Jr. to leave Nike board after eight years of service
• Micron Technology (MU) PT Raised to $1,300 at Bernstein SocGen Group
• Berenberg Downgrades Umicore SA (UMI:BB) (UMICY) to Hold